Trending Now
KULR Technology Group Inc (OTCMKTS:KULR) Connects 3D Printing and Space Commercialization...
Space. The Final Frontier. As with any frontier in human culture, there are two main steps: 1. Exploration and discovery; and 2....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) Gets Back on the Map with...
Charlotte's Web Holdings Inc (OTCMKTS:CWBHF) is a leader in the CBD space based on market penetration over recent years.
MAKE IT MODERN
LATEST REVIEWS
Small Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment...
The addiction treatment space has been pummeled along with everything else in the growth side of the stock market so far in...
MAKE IT MODERN
PERFORMANCE TRAINING
Novan Inc. (NASDAQ:NOVN) Offers Pipeline Update On Various Developmental Programs
Novan Inc. (NASDAQ:NOVN) has released a priority update about its lead product SB206, which they are currently evaluating in a pivotal third phase B-SIMPLE...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expects To Post Revenues Of $245 Million In 2020: Receives...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) achieved several milestones in Q2 2020. CEO of Halozyme, Helen Torley, said the company also received FDA approval for partnered...
Onconova Therapeutics Inc. (NASDAQ: ONTX) Releases Safety And Efficacy Data of Rigosertib-Nivolumab Combination
Onconova Therapeutics Inc. (NASDAQ: ONTX) has releases interim efficacy and safety data from the investigator-initiated Phase 1/2, a study of oral rigosertib combination with...
Seelos Therapeutics Inc.’s (NASDAQ: SEEL) SLS-005 Included in the HEALEY ALS Platform Trial
The Sean M. Healey & AMAG Centre for ALS at Mass General has received FDA approval, and The Mass General Brigham Institutional Review Board...
Longeveron Inc. (NASDAQ: LGVN) Announces Orphan Drug Designation Grant For Lomecel-B Drug on HLHS
Longeveron Inc. (NASDAQ: LGVN) has announced that the FDA has granted its Lomecel-B drug for Hypoplastic Left Heart Syndrome treatment an Orphan Drug Designation....
MAKE IT MODERN
